Does the media favor CRSP or CGEM?

In the previous week, Cullinan Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 8 mentions for CRISPR Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.23 beat CRISPR Therapeutics' score of 0.77 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGEM or LGND?

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat Cullinan Therapeutics' score of 1.23 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGEM or GRFS?

In the previous week, Cullinan Therapeutics had 10 more articles in the media than Grifols. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 3 mentions for Grifols. Cullinan Therapeutics' average media sentiment score of 1.23 beat Grifols' score of 0.88 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or CGEM?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 13 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.23 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, EWTX or CGEM?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A

Is EWTX or CGEM more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media refer more to EWTX or CGEM?

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Cullinan Therapeutics' score of 1.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cullinan Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cullinan Therapeutics (CGEM) Competitors

$21.70 -0.90 (-3.98%)

As of 08/28/2026 04:00 PM Eastern

Compare

CGEM vs. CRSP, LGND, GRFS, ACAD, and EWTX

Should you buy Cullinan Therapeutics stock or one of its competitors? Cullinan Therapeutics's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Ligand Pharmaceuticals (LGND), Grifols (GRFS), ACADIA Pharmaceuticals (ACAD), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Cullinan Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$11M	507.37	-$581.60M	-$4.76	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

In the previous week, Cullinan Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 8 mentions for CRISPR Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.23 beat CRISPR Therapeutics' score of 0.77 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 17.91%. Cullinan Therapeutics has a consensus target price of $32.86, suggesting a potential upside of 51.42%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Cullinan Therapeutics beats CRISPR Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Ligand Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Cullinan Therapeutics currently has a consensus target price of $32.86, indicating a potential upside of 51.42%. Ligand Pharmaceuticals has a consensus target price of $335.75, indicating a potential upside of 19.70%. Given Cullinan Therapeutics' higher possible upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cullinan Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat Cullinan Therapeutics' score of 1.23 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to Cullinan Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Ligand Pharmaceuticals	$268.09M	20.86	$124.45M	$9.35	30.00

Summary

Ligand Pharmaceuticals beats Cullinan Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Grifols?

Cullinan Therapeutics (NASDAQ:CGEM) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Cullinan Therapeutics currently has a consensus target price of $32.86, suggesting a potential upside of 51.42%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 30.04%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cullinan Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Cullinan Therapeutics had 10 more articles in the media than Grifols. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 3 mentions for Grifols. Cullinan Therapeutics' average media sentiment score of 1.23 beat Grifols' score of 0.88 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to Cullinan Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Grifols	5.54%	6.21%	2.39%

Cullinan Therapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Grifols has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.47

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cullinan Therapeutics and Grifols tied by winning 8 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Cullinan Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 13 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.23 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals currently has a consensus price target of $34.36, indicating a potential upside of 18.04%. Cullinan Therapeutics has a consensus price target of $32.86, indicating a potential upside of 51.42%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

ACADIA Pharmaceuticals beats Cullinan Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Edgewise Therapeutics presently has a consensus price target of $50.33, suggesting a potential upside of 17.71%. Cullinan Therapeutics has a consensus price target of $32.86, suggesting a potential upside of 51.42%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Cullinan Therapeutics' score of 1.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cullinan Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics' return on equity of -39.01% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Edgewise Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Summary

Edgewise Therapeutics beats Cullinan Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.40B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-7.00	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.34	16.53	12.98	6.14
Net Income	-$219.88M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.09%	-0.31%	0.13%	-0.80%
1 Month Performance	23.86%	9.80%	7.08%	4.13%
1 Year Performance	187.80%	55.66%	24.67%	15.17%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.0914 of 5 stars	$21.70 -4.0%	$32.86 +51.4%	+187.8%	$1.40B	N/A	N/A	30	News Coverage
CRSP CRISPR Therapeutics	2.3114 of 5 stars	$60.42 +5.9%	$68.06 +12.6%	+11.4%	$5.83B	$3.51M	N/A	460	Analyst Forecast
LGND Ligand Pharmaceuticals	4.1101 of 5 stars	$282.30 +0.8%	$335.75 +18.9%	+73.5%	$5.64B	$290.54M	30.25	80	Positive News
GRFS Grifols	4.6671 of 5 stars	$8.04 +0.6%	$10.00 +24.5%	-22.9%	$5.47B	$8.51B	42.27	25,247
ACAD ACADIA Pharmaceuticals	4.6803 of 5 stars	$30.57 +3.1%	$34.36 +12.4%	+12.0%	$5.26B	$1.07B	13.76	510	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. CRSP, LGND, GRFS, ACAD, and EWTX

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

Summary

How does Cullinan Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Grifols?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. CRSP, LGND, GRFS, ACAD, and EWTX

How does Cullinan Therapeutics compare to CRISPR Therapeutics?

Which has preferable earnings & valuation, CRSP or CGEM?

Does the media favor CRSP or CGEM?

Which has more risk and volatility, CRSP or CGEM?

Do institutionals and insiders hold more shares of CRSP or CGEM?

Is CRSP or CGEM more profitable?

Do analysts rate CRSP or CGEM?

Summary

How does Cullinan Therapeutics compare to Ligand Pharmaceuticals?

Do analysts rate CGEM or LGND?

Which has more risk & volatility, CGEM or LGND?

Does the media refer more to CGEM or LGND?

Is CGEM or LGND more profitable?

Do institutionals & insiders hold more shares of CGEM or LGND?

Which has stronger earnings & valuation, CGEM or LGND?

Summary

How does Cullinan Therapeutics compare to Grifols?

Do analysts recommend CGEM or GRFS?

Does the media refer more to CGEM or GRFS?

Is CGEM or GRFS more profitable?

Which has more volatility & risk, CGEM or GRFS?

Which has preferable valuation and earnings, CGEM or GRFS?

Do institutionals and insiders hold more shares of CGEM or GRFS?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Which has preferable valuation & earnings, ACAD or CGEM?

Which has more risk and volatility, ACAD or CGEM?

Is ACAD or CGEM more profitable?

Do insiders and institutionals hold more shares of ACAD or CGEM?

Does the media prefer ACAD or CGEM?

Do analysts recommend ACAD or CGEM?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Do analysts recommend EWTX or CGEM?

Do institutionals and insiders have more ownership in EWTX or CGEM?

Does the media refer more to EWTX or CGEM?

Is EWTX or CGEM more profitable?

Which has stronger valuation and earnings, EWTX or CGEM?

Which has more risk and volatility, EWTX or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools